PRCT Shareholder Alert: September 22, 2026 Lead Plaintiff Deadline in PROCEPT BIOROBOTICS CORPORATION Securities Class Action - Contact Levi & Korsinsky

Shareholders who acquired PRCT shares during the October 2024 registered public offering are urged to review allegations that offering-period disclosures failed to reveal a discount-driven handpiece ordering program and excess field inventory risk.

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP announces that a securities class action has been filed against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of shareholders who purchased securities between February 28, 2024 and February 25, 2026. Find out if you might qualify for recovery. You may also contact Joseph E. Levi, Esq. at [e-mail] or [phone].

PRCT shares declined more than 75% from a Class Period high of approximately $100.00 to less than $25.00, a drop of more than $75.00 per share. The October 2024 registered public stock offering raised roughly $175 million. Motions for lead plaintiff must be filed with the Court by September 22, 2026.

Registration Statement Securities Fraud Allegations in the October 2024 Offering

The action contends that Procept’s offering-period disclosures and related public statements presented handpiece sales growth and utilization trends as indicators of durable procedure demand. As pleaded, the Company allegedly failed to disclose that a discount program was encouraging customers to place bulk orders above actual procedure needs.

The complaint asserts that Procept’s recurring revenue model made handpiece sales especially important to investors because each single-use handpiece generated approximately $3,200 in revenue and handpiece sales had become a substantial share of total revenue.

What the Registered Offering Materials Allegedly Misrepresented

Plaintiffs allege that shareholders evaluating the registered public offering were not adequately informed that:

• Procept allegedly used an undisclosed discount program to incentivize quarter-end bulk handpiece orders;
• handpiece unit sales allegedly exceeded actual procedures in every quarter since the first quarter of 2023;
• reported sales allegedly pulled forward demand from later periods;
• field inventory allegedly accumulated to more than 10,000 excess handpieces by the end of the Class Period;
• insiders allegedly sold approximately $90 million in PRCT shares during the Class Period while the stock price was allegedly inflated.

Why the SPO Allegations Matter to PRCT Shareholders

The lawsuit claims that the $175 million registered public offering is significant because it occurred while Procept’s share price was allegedly inflated by statements about utilization, procedure growth, and recurring handpiece demand. The action turns on allegations that investors were not told that sales growth depended in part on overstocking customers through undisclosed discounts.

"The PSLRA provides important protections for investors harmed by alleged securities violations, including investors who acquired shares in registered offerings while material risks were allegedly withheld. Here, the complaint raises specific questions about whether PRCT shareholders received complete information about handpiece demand and field inventory before the market repriced the stock." -- Joseph E. Levi, Esq.

Submit your information now or call [phone].

WHY LEVI & KORSINSKY — Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors. Investors who suffered losses have until September 22, 2026 to seek appointment as lead plaintiff.

Frequently Asked Questions About the PRCT Lawsuit

Q: Who is eligible to participate in the PRCT investor lawsuit? A: Investors who purchased PRCT stock or securities between February 28, 2024 and February 25, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: What specific misstatements does the PRCT lawsuit allege? A: The complaint alleges PROCEPT BioRobotics Corporation made materially false or misleading statements regarding handpiece utilization, customer ordering patterns, procedure demand, field inventory, and the impact of an undisclosed discount program during the Class Period. When the Company disclosed actual procedure data and the extent of excess handpiece inventory, the stock price declined sharply.

Q: What court was the PRCT class action filed in? A: The case was filed in the United States District Court for the Northern District of California, San Jose Division, and is governed by the Private Securities Litigation Reform Act of 1995.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What documents should PRCT investors preserve? A: Investors should preserve brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my PRCT shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to request an evaluation. Securities class actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs. Any attorneys' fees and expenses awarded to class counsel are subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.